The Filing Desk

Gyre Therapeutics vs UroGen Pharma

Gyre Therapeutics GYRE · UroGen Pharma URGN · Pharmaceuticals

Gyre Therapeutics reported revenue of $117 million in fiscal 2025, about the same as UroGen Pharma's $110 million in fiscal 2025. Gyre Therapeutics' revenue grew 10.2% in its latest year, and UroGen Pharma's grew 21.4%. Gyre Therapeutics had an operating margin of 9.8%, against -113.7% at UroGen Pharma. Free cash flow was −$0 million at Gyre Therapeutics and −$163 million at UroGen Pharma.

Side by side

Gyre TherapeuticsUroGen Pharma
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$117M$110M
Revenue growth10.2%21.4%
Revenue growth a year, last 5 years41.0%56.2%
Gross margin95.3%88.7%
Operating margin9.8%−113.7%
Net margin8.5%−139.8%
Free cash flow−$0M−$163M
Free cash flow margin−0.1%−148.2%
Return on capital9.7%—
Net debt to EBITDA−3.8x—
Dividends and buybacks$0M$0M
Change in diluted share count0.9%12.2%
Last close$4.52$31.73
P/E at the last close——
Insider trades, last 12 monthssold $952,874sold $4.4 million
Piotroski F-score4 of 92 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Gyre TherapeuticsUroGen Pharma
Operating margin
Percent of revenue
Gyre TherapeuticsUroGen Pharma
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Gyre TherapeuticsUroGen Pharma

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Gyre Therapeutics and UroGen Pharma pages.